BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/20/2023 11:48:41 PM | Browse: 77 | Download: 105
| Publication Name |
World Journal of Gastroenterology |
| Manuscript ID |
80502 |
| Country/Territory |
India |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Deepa S Mandlik, Satish K Mandlik and Heena B Choudhary |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Deepa S Mandlik, PhD, Assistant Professor, Department of Pharmacology, BVDU, Poona College of Pharmacy, Kothrud, Pune 411038, Maharashtra, India. deepa.mandlik@bharatividyapeeth.edu |
| Key Words |
Hepatocellular carcinoma; Immunotherapy; Immune checkpoint inhibitors; Alpha-fetoprotein; Cancer vaccine; Combination therapies |
| Core Tip |
Core Tip: Hepatocellular carcinoma (HCC) is a multifaceted illness with multiple faces. It avoids early discovery, which provides the best chance of cure by resection/transplant, and systemic treatments are only of marginal efficacy at best, despite recent therapeutic advances. Current advances in immunotherapy and its combinations have altered the HCC treatment landscape, and clinical studies are continuing to pave the path forward. Immunotherapy increases survival rates and provides long-term cancer control in subsets of HCC patients while also minimising side effects. Further research into immunotherapy in combination with current treatments for HCC in the early and intermediate stages may assist a greater spectrum of patients. Continued research into programmed cell death 1/ programmed cell death ligand 1, TMB, ctDNA, microsatellite stability, DNA mismatch repair, neutrophil/lymphocyte ratio, cytokines, and cellular peripheral immune response will hopefully identify the most reliable marker for selecting and sequencing systemic treatments to achieve the best outcome in HCC patients. Despite such significant treatment advances in HCC, numerous hurdles remain. The scientific community must figure out how to appropriately sequence these medicines for the best potential response, how to control toxicities, and how to develop indicators to monitor for response and relapse. |
| Citation |
Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol 2023; 29(6): 1054-1075 |
 |
Received |
|
2022-09-29 16:19 |
|
Peer-Review Started |
|
2022-09-29 16:20 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-12-12 08:16 |
|
Revised |
|
2022-12-23 06:26 |
|
Second Decision |
|
2023-01-20 03:30 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-01-20 23:48 |
|
Articles in Press |
|
2023-01-20 23:48 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-01-27 17:59 |
|
Typeset the Manuscript |
|
2023-01-30 07:07 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Assistant Editor |
Assistant Editor |
| Science Editor |
Yu-Lu Chen |
| Reviewer Code |
06272301, and 06457333 |
| Editorial Director |
|
| Journal Chief Editor |
|
| Company Chief Editor |
Li Ma |
| Language Editor |
Donna Fox |
| Production Editor |
Hua-Ge Yu |
| Responsible Production Editor |
Hua-Ge Yu |
| Responsible Science Editor |
|
| Proofing Editorial Director |
Jin-Lei Wang |
| Proofing Editor-in-Chief |
Lian-Sheng Ma |
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
